2026-04-04 · Consumer-facing antimicrobial resistance intelligence — translating WHO, CDC, and ECDC surveillance data into beautiful, actionable threat reports, pathogen scorecards, city-level risk maps, and weekly "resistance dispatches" that tell people which drugs are failing, where, and what it means for their family.

Bug Ledger

The superbugs are winning. Here's the scoreboard.

Channel: Bug Ledger Tagline: The superbugs are winning. Here’s the scoreboard. Niche: Consumer-facing antimicrobial resistance intelligence — translating WHO, CDC, and ECDC surveillance data into beautiful, actionable threat reports, pathogen scorecards, city-level risk maps, and weekly “resistance dispatches” that tell people which drugs are failing, where, and what it means for their family. Target audience: Health-conscious adults (25–55) who read about science but can’t parse academic papers. Parents worried about antibiotic overuse in kids. Travelers wanting to know resistance risks by destination. Healthcare workers frustrated that patients don’t understand AMR. Prepper-adjacent folks worried about a post-antibiotic future. Effective Altruism community members tracking existential/catastrophic risks. Why now: The Lancet published the landmark forecast (Sept 2024): 39 million deaths directly from AMR by 2050, up from ~1.27M/year currently. WHO launched an enhanced AMR dashboard in 2025. Candida auris outbreaks have entered mainstream consciousness. The “post-antibiotic era” is no longer hypothetical — yet there is ZERO consumer-facing, beautifully designed, regularly updated content that makes this data accessible. The CDC just released a 2026 AMR Communications Toolkit, acknowledging the massive awareness gap. This is the climate change of infectious disease — everyone should care, almost nobody can access the data.

Content Example

🔴 Resistance Report #47: Klebsiella Is Eating Your Last-Line Antibiotics for Breakfast

Bug Ledger Weekly — April 4, 2026

There’s a bacterium in hospitals right now that can survive carbapenems — the antibiotics doctors reach for when nothing else works. Its name is Klebsiella pneumoniae, and according to new GLASS data, its resistance to carbapenems has crossed the 30% threshold in 12 more countries since last year.

Let that sink in. Thirty percent of tested Klebsiella samples in these countries shrug off the drugs of last resort.

The Numbers Nobody Showed You

WHO’s surveillance network reported that carbapenem-resistant K. pneumoniae (CRKP) now exceeds 50% resistance in 8 nations, up from 5 just two years ago. In Southeast Asia and parts of the Eastern Mediterranean, we’re seeing rates above 65%. This isn’t an outbreak — it’s a trend line, and it’s pointing straight up.

Here’s what that means in practice: If your grandmother gets a urinary tract infection caused by CRKP in a hospital in one of these countries, the doctor has maybe two treatment options left. Maybe. One of those — colistin — was abandoned in the 1970s because of kidney toxicity and brought back out of desperation. The other — ceftazidime-avibactam — costs hundreds of dollars per course and isn’t available in most of the world.

The Resistance Map — April 2026

[GENERATED: Choropleth world map showing CRKP resistance percentages by country, colored from green (<10%) through yellow (10-30%) to deep red (>50%). Interactive version on site allows clicking any country for trend data.]

Why This Matters To You Personally

You don’t need to be in a hospital in Pakistan or Greece to be affected. Resistant bacteria travel — in people, in food, in water. A study in The Lancet Infectious Diseases tracked CRKP strains from a single hospital in Italy across 7 European countries within 18 months. Your local hospital’s resistance profile is shaped by global movement.

What you can actually do:

• Ask your doctor: “Is an antibiotic actually necessary here?” (40% of outpatient antibiotic prescriptions in the US are unnecessary — CDC data)
• Check your hospital: Bug Ledger’s Hospital Resistance Lookup uses CMS and state health department data to show resistance rates at facilities near you
• Travel smart: Our Destination Resistance Guide shows which antibiotics may not work in countries you’re visiting — and what your travel doctor should know

The Pipeline Problem

Only 13 new antibiotics were approved between 2017 and 2023. Of those, only 2 target the WHO’s “critical priority” pathogens. The antibiotic pipeline isn’t just thin — it’s hemorrhaging companies. Since 2018, Achaogen, Melinta, and Tetraphase all went bankrupt after getting FDA approval for new antibiotics. The business model is broken: the best antibiotics are the ones used least (to prevent resistance), which means the lowest sales.

Bug Ledger’s Verdict: CRKP is the clearest signal that we are losing the antibiotic race. Not in 2050. Now. The data has been public in WHO databases for years — but nobody translated it into language humans can read. That’s what we’re here for. 🔴

Sources: WHO GLASS 2025 data release, CDC AR Threats Update, Lancet Infectious Diseases doi:10.1016/S1473-3099(24)00089-1

Data Sources

• WHO GLASS Dashboard (data.who.int/dashboards/amr) — Global AMR surveillance: resistance percentages by pathogen, antibiotic, country. Updated annually + interim releases. Free download/API. This is the backbone.
• CDC NARMS Now (wwwn.cdc.gov/NARMSNow) — US enteric bacteria resistance data. Interactive, downloadable. Updated quarterly.
• CDC AR Threats Reports — Published pathogen-specific resistance data and death estimates for US.
• ResistanceMap / One Health Trust (resistancemap.cddep.org) — Global antibiotic resistance and consumption data. Free.
• BV-BRC / PATRIC API (patricbrc.org/api/doc/) — Bacterial genome database with AMR metadata. REST API, MIT license. Can track genomic resistance gene spread.
• ECDC Surveillance Atlas — European resistance data by country, pathogen, antibiotic. Annual published datasets.
• PubMed E-utilities API — Auto-search for new AMR research. Parse titles/abstracts for key findings. Free, rate-limited.
• ClinicalTrials.gov API — Track active antibiotic/antifungal trials, completion dates, results. Free.
• FDA openFDA API — New drug approvals, including antibiotics. Free.
• ProMED-mail RSS — Real-time outbreak alerts including AMR events. Free.
• bioRxiv/medRxiv API — AMR pre-prints for bleeding-edge research. Free.
• PEW Charitable Trusts Antibiotic Pipeline — Tracks drugs in development. Published data.

Automation Pipeline

• Schedule: GitHub Actions runs daily at 06:00 UTC (main dispatch) + weekly deep-dive Sundays
• Collect:
  • Daily: Scrape WHO GLASS dashboard for new data releases. Query PubMed API for new AMR papers (last 24h). Check ProMED RSS for outbreak alerts. Check ClinicalTrials.gov for new/completed antibiotic trials.
  • Weekly: Pull ResistanceMap data snapshots. Compare to previous week for trend detection. Check FDA for new approvals.
  • Monthly: Full GLASS data refresh, country-level comparison update.
• Process:
  • AI (Claude/GPT-4) analyzes collected data: identifies statistically significant changes, new resistance threshold crossings, notable research findings
  • Generates “Resistance Report” article with structured sections: The Numbers, The Map, Why It Matters, What You Can Do, Pipeline Update
  • Cross-references new data against historical baselines to surface trends
  • Generates image prompts for maps, charts, pathogen cards
• Generate:
  • Choropleth resistance maps via D3.js (server-side rendered to SVG/PNG)
  • Trend charts (resistance % over time by pathogen) via Chart.js
  • “Pathogen Threat Cards” — AI-illustrated bacteria with risk meters
  • Pipeline infographics — drug development stages visualization
  • Country/city risk scorecards
• Publish: Astro static build → GitHub Pages. Automated PR for review (optional) or direct deploy.

Tech Stack

• Static site: TypeScript + Astro (content collections, MDX support, excellent performance)
• Data collection: Node.js scripts (fetch + cheerio for scraping, axios for APIs)
• Image generation: D3.js (server-side) for data viz, AI image generation for pathogen illustrations and hero images
• Data processing: TypeScript data pipeline with statistical comparison logic
• Charts: Chart.js or Observable Plot for interactive charts on the frontend
• Search: Pagefind (static search, perfect for Astro)
• CI/CD: GitHub Actions (daily + weekly cron triggers)
• Hosting: GitHub Pages (free) or Cloudflare Pages (free tier, faster global CDN)
• Newsletter: Buttondown (free tier up to 100 subscribers, then paid) or Listmonk (self-hosted, free)

Monetization Model

• Tier 1 — Donations/Tips:
  • Buy Me a Coffee / Ko-fi — “Help us track the bugs that track you”
  • GitHub Sponsors — for the open-source data pipeline
  • Projected: $200–500/mo once established (health content donors are generous)
• Tier 2 — Newsletter Premium:
  • Free weekly dispatch for everyone
  • Premium: monthly deep-dive reports, early pathogen alerts, downloadable data, travel resistance guides
  • $5/mo or $40/year
  • Projected: 200 subscribers at month 6 = $1,000/mo
• Tier 3 — Affiliate/Contextual:
  • Water purification products (on PFAS-adjacent content)
  • Travel health insurance (on destination resistance guides)
  • Probiotics/gut health products (with honest reviews, not shill content)
  • Projected: $300–800/mo at scale
• Tier 4 — Institutional:
  • Hospitals, public health departments licensing the data dashboard
  • Pharma companies sponsoring “pipeline tracker” section
  • Long-term play, $5K+ deals
• Projected month-1 revenue: $50–150 (donations, early newsletter signups)
• Projected month-6 revenue: $1,500–3,000 (newsletter growth, affiliate traction, SEO compounding)

The Soul of Bug Ledger

Name: Bug Ledger — because someone needs to keep score in the war we’re losing.

Mascot: A cartoon bacterium in a tiny business suit, carrying a briefcase labeled “RESISTANCE GENES.” Named Rex (Resistance Expert). Rex shows up in article headers looking smug, concerned, or alarmed depending on the news. Sometimes he wears a tiny hard hat. Sometimes he’s sweating.

Voice: A former science journalist who quit mainstream media because nobody would let them write about AMR with the urgency it deserves. Sharp, slightly dark humor. Uses analogies that make complex microbiology viscerally understandable. Not alarmist — factual, which is alarming enough. Think Michael Lewis writing about bacteria instead of finance. The kind of voice that says “here are the numbers, draw your own conclusions” and then makes damn sure the conclusions are obvious.

Opinion: Bug Ledger believes (and says so):

• The antibiotic business model is fundamentally broken and needs public subsidy like fire departments
• Hospital infection data should be as public and easy to read as restaurant health inspections
• Antibiotic use in livestock is an indefensible scandal that gets a fraction of the outrage it deserves
• Consumer education on AMR is the biggest public health communication failure since pre-seatbelt driving
• The “10 million deaths by 2050” figure is probably an undercount

Running jokes & traditions:

• “Rex’s Weekly Mood” — the mascot’s expression on the homepage changes based on the week’s data (😐 Concerned → 😰 Sweating → 🔴 Code Red)
• “The Shrug Test” — rating how many antibiotics a pathogen can shrug off (1-shrug = resistant to one class, 5-shrug = pan-resistant nightmare)
• “Drug Obituaries” — when a study shows an antibiotic crossing the uselessness threshold for a pathogen in a region, Bug Ledger publishes a tongue-in-cheek obituary
• “Pipeline Bingo” — monthly tracking of which antibiotic companies went bankrupt, merged, or abandoned development
• Friday “Good Bug News” — one positive development each week (new phage therapy result, successful stewardship program, etc.)

Visual style: Medical-data meets punk zine. Deep navy background, neon green (#00FF88) accent color (evokes bacterial fluorescence), bold sans-serif typography. Data visualizations use a red-amber-green traffic light system. Pathogen threat cards look like trading cards. Clean, dense with information, but never cluttered.

Growth Mechanics

• SEO: Target long-tail health queries: “is amoxicillin still effective 2026”, “MRSA risk [city]”, “superbug travel [country]”, “antibiotic resistance explained”. Health content with proper E-E-A-T signals ranks well.
• Social sharing hooks: The resistance maps and pathogen threat cards are extremely shareable. “Drug Obituaries” are inherently viral. Rex the mascot creates meme potential.
• Newsletter capture: Every article ends with “Get the weekly dispatch — the superbugs won’t wait.” Free tier is genuinely good.
• Reddit/community: Share weekly reports in r/microbiology, r/medicine, r/science. Engage honestly, don’t spam.
• Healthcare worker amplification: Make content that nurses and doctors WANT to share with patients. They’re desperate for accessible AMR education.
• Effective Altruism community: AMR is a recognized EA cause area. Cross-post analysis to EA Forum.
• Academic citation: If the data analysis is rigorous, researchers will cite and link to Bug Ledger — massive authority signal.

Scores

Launch Complexity: 3/5 — Multiple APIs to integrate, but all are well-documented and free. The challenge is the data normalization pipeline across WHO/CDC/ECDC formats. 2-3 weeks for a strong MVP.

Content Quality Score: 5/5 — Health data journalism with real sources, proper citation, actionable advice. The sample article above demonstrates: specific numbers, sourced claims, practical “what to do” sections, and genuine insight. This isn’t summarization — it’s analysis.

Automation Score: 4/5 — Daily data collection is fully automatable. AI writing from structured data works well for this format. The main manual input is editorial judgment on which data points are most important each week — but even this can be approximated by statistical significance detection. Image generation for maps/charts is 100% programmatic.

Revenue Potential: 5/5 — Health niche commands high CPMs and donor willingness. The newsletter premium ($5/mo) is well below “health information” willingness-to-pay. Institutional licensing is a real upside. Affiliate (travel health, water filters) is contextually perfect. And the mission-driven angle (“help us track the crisis nobody’s tracking”) drives donations hard.

Total: 17/20

Why This Will Work

Psychology: Fear + empowerment. People are terrified of superbugs (every Candida auris headline proves this) but feel helpless because the information is inaccessible. Bug Ledger gives them the data AND the actions. This is the same psychology that makes weather apps addictive — uncertainty + information = engagement.

Market logic: AMR is the next climate change in terms of public consciousness trajectory. Right now we’re at the “Al Gore making a documentary” stage. The site that establishes itself as THE accessible, trustworthy AMR source now will own the category when mainstream awareness hits. First-mover advantage in a guaranteed-to-grow niche.

Data richness: WHO GLASS alone provides enough structured data to generate content for years. Add CDC NARMS, ECDC, PubMed, and clinical trials, and you have a firehose of raw material. The automation never runs dry.

Donation psychology: People donate to voices, not institutions. Rex the mascot + the opinionated editorial voice + genuine public service = the recipe for a Patreon/Ko-fi flywheel. “I donated $5 to the bacteria scoreboard” is a great conversation starter.

Risk & Mitigation